Limited contribution of CYP3A5 to the hepatic 6β-hydroxylation of testosterone

[1]  Peter Neuhaus,et al.  Sex is a major determinant of CYP3A4 expression in human liver , 2003, Hepatology.

[2]  M. Ingelman-Sundberg,et al.  Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[3]  Tetsuo Satoh,et al.  Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. , 2003, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[4]  Shiew-Mei Huang,et al.  Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[5]  Jin‐ding Huang,et al.  Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[6]  J. Brockmöller,et al.  Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[7]  B. Goh,et al.  Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B. Ring,et al.  Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[9]  M. Haberl,et al.  The genetic determinants of the CYP3A5 polymorphism. , 2001, Pharmacogenetics.

[10]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[11]  A. Paterson,et al.  Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. , 2000, Pharmacogenetics.

[12]  A Gouyette,et al.  Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  M. Kinirons,et al.  Effects of ketoconazole on the erythromycin breath test and the dapsone recovery ratio. , 1999, British journal of clinical pharmacology.

[14]  D. Kroetz,et al.  Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe. , 1998, Biochemistry.

[15]  P. Neuvonen,et al.  The area under the plasma concentration–time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin , 1998, European Journal of Clinical Pharmacology.

[16]  D. Shen,et al.  Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.

[17]  M. Eichelbaum,et al.  Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[18]  G. Wilkinson.  Cytochrome P4503A (CYP3A) metabolism: Prediction ofIn Vivo activity in humans , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[19]  K. Korzekwa,et al.  Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. , 1995, Biochemical pharmacology.

[20]  H. Yamazaki,et al.  Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5' modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. , 1995, Archives of biochemistry and biophysics.

[21]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[22]  S D Hall,et al.  Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.

[23]  J. Groopman,et al.  Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men , 1993, Clinical pharmacology and therapeutics.

[24]  S. Wrighton,et al.  Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.

[25]  P. Beaune,et al.  Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. , 1990, The Journal of pharmacology and experimental therapeutics.

[26]  S. Bandiera,et al.  Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.